GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference
Topics/Gallbladder and Pancreas/Native Hawaiian pancreatic cancer disparity study

Native Hawaiian pancreatic cancer disparity study

Clinical knowledge base curated and reviewed by GastroAGI TeamLast updated July 1, 2025

Quick Answer

The study on pancreatic cancer disparities among Native Hawaiians, conducted as part of the Multiethnic Cohort Study, revealed significant findings about the heightened risk faced by this population compared to White individuals. Below is a detailed summary of the study and its findings: ### Key Findings: 1.


The study on pancreatic cancer disparities among Native Hawaiians, conducted as part of the Multiethnic Cohort Study, revealed significant findings about the heightened risk faced by this population compared to White individuals. Below is a detailed summary of the study and its findings:

### Key Findings:

1. **Elevated Risk of Pancreatic Cancer:**

  • Native Hawaiians were found to have a **71% higher risk of pancreatic cancer** compared to White individuals, even after adjusting for established risk factors such as diabetes, obesity, smoking, alcohol use, and family history of cancer.
  • The incidence rates of pancreatic cancer were nearly double in Native Hawaiians (80.2 per 100,000 person-years) compared to Whites (44.6 per 100,000 person-years).

2. **Gender-Specific Risk:**

  • The elevated risk persisted across both sexes:
  • **Men:** Hazard Ratio (HR) of 1.54.
  • **Women:** Hazard Ratio (HR) of 1.85.
  • This indicates that Native Hawaiian women face an even higher relative risk compared to White women.

3. **Impact of Comorbidities:**

  • Risk of pancreatic cancer increased with the number of comorbidities (e.g., diabetes, obesity, smoking, alcohol use, or family history of cancer).
  • Native Hawaiian men with **two or more risk factors** had a **fivefold greater risk** compared to White men without any risk factors (HR 5.17).

4. **Diabetes as a Key Risk Factor:**

  • Among Native Hawaiian men, diabetes was particularly impactful, tripling the risk of pancreatic cancer.

5. **Genetic and Environmental Contributions:**

  • Genetic analyses suggested that the elevated risk in Native Hawaiians was **independent of polygenic risk scores**, indicating that other biological or environmental factors may be contributing to the disparity.

### Implications:

The study concluded that the disproportionate burden of pancreatic cancer in Native Hawaiians likely stems from the **higher prevalence and cumulative effect of risk factors** in this population, particularly among men. This highlights the need for targeted interventions to address these disparities.

### Recommendations:

1. **Targeted Prevention Strategies:**

  • Developing culturally tailored prevention strategies to address modifiable risk factors such as diabetes, obesity, smoking, and alcohol use.

2. **Risk-Factor Modification:**

  • Aggressive efforts to manage and reduce risk factors in high-risk Native Hawaiian populations.

3. **Exploration of Screening:**

  • Researchers emphasized the potential benefits of exploring pancreatic cancer screening for high-risk Native Hawaiian individuals, given their elevated risk.

4. **Further Research:**

  • Additional genetic and longitudinal studies are needed to better understand the mechanisms driving these disparities and to identify other potential contributors, whether biological, environmental, or social.

### Conclusion:

The findings underscore the urgent need to address the unique health challenges faced by Native Hawaiians, particularly in the context of pancreatic cancer. By focusing on prevention, early detection, and further research, health disparities in this population can be better understood and mitigated.

Related Q&A

Ivonescimab Plus Gemcitabine–Cisplatin in Biliary Tract Cancer (BTC): Journal of Hepatology | July 2026

Introduction: Advanced biliary tract cancer (BTC) carries a poor prognosis, with limited improvements in survival despite the addition of immune checkpoint inhibitors to standard gemcitabine–cisplatin chemotherapy. This phase II trial evaluated ivonescimab, a novel PD-1/VEGF...

GLP-1 Receptor Agonists and Gallbladder Disease: UEG Journal | June 2026

Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become a cornerstone in the management of type 2 diabetes because of their excellent glycemic, cardiovascular, and weight-loss benefits. However, concerns remain regarding their potential association with...

Remnant Duct Dilatation Rarely Signals IPMN Recurrence : Ann Surg | Jun 2026

Introduction: Patients undergoing pancreatoduodenectomy for non invasive intraductal papillary mucinous neoplasm (IPMN) require long-term surveillance because of the risk of disease recurrence in the pancreatic remnant. New pancreatic duct (PD) dilatation is commonly detected during...

Post-Pancreatectomy Chyle Leak: Annals of Surgery | June 2026

• This study evaluated 1,063 patients undergoing pancreatic surgery; 11% developed conventionally defined chyle leak. • Most clinically relevant cases were grade B, while no grade C leaks were reported. • A minimally invasive surgical...

Immediate Necrosectomy Accelerates Recovery in Walled-Off Necrosis : Gastroenterology | Jul 2026

Introduction: Endoscopic ultrasound (EUS)-guided drainage has become the preferred minimally invasive treatment for symptomatic necrotizing pancreatitis. However, the optimal timing of direct endoscopic necrosectomy (DEN) following drainage remains uncertain. While the conventional step-up approach reserves...

Fatty Pancreas: A Hidden Burden in T2DM : Diabetes Res Clin Pract | June 2026

Introduction: Fatty pancreas disease (FPD), also known as intrapancreatic fat deposition, has emerged as an important metabolic condition closely linked to obesity, insulin resistance, and type 2 diabetes mellitus (T2DM). Although ectopic fat accumulation in...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer